Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94

Rhea-AI Filing Summary

Seres Therapeutics director grants stock options

Seres Therapeutics, Inc. director Robert L. Rosiello received a grant of stock options covering 7,508 shares of common stock at an exercise price of $7.94 per share. These options were awarded as compensation rather than purchased on the open market.

The options vest in four equal quarterly installments on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, with the final installment vesting earlier if the 2027 annual stockholder meeting occurs before July 1, 2027, subject to his continued service on the board as a non-employee director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rosiello Robert L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,508	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 7,508 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 7,508 options Exercise price: $7.94 per share Post-transaction options held: 7,508 options +2 more

5 metrics

Options granted 7,508 options Stock option grant to director Robert L. Rosiello

Exercise price $7.94 per share Exercise price of newly granted stock options

Post-transaction options held 7,508 options Total derivative securities following the grant

Option expiration July 1, 2036 Expiration date of the stock options

Vesting dates Oct 1 2026 – Jul 1 2027 Four equal quarterly vesting installments

Key Terms

Stock Option (right to buy), exercise price, vesting, non-employee director, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "7.9400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests and becomes exercisable in four equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

non-employee director financial

"subject to the reporting person continuing in service on the Board as a non-employee director"

annual meeting of stockholders financial

"if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 06:10 PM Accepted by SEC EDGAR 07/02/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosiello Robert L.

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.94	07/01/2026		A		7,508		(1)	07/01/2036	Common Stock	7,508	$0	7,508	D

Explanation of Responses:

1. The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date.

	/s/ Thomas J. DesRosier, Attorney-in-Fact for Robert L. Rosiello	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Seres Therapeutics (MCRB) director Robert L. Rosiello receive in this Form 4?

Robert L. Rosiello received a grant of stock options for 7,508 shares of Seres Therapeutics common stock. The options carry a $7.94 exercise price and represent compensation as a non-employee director rather than an open-market share purchase.

What is the exercise price of the new Seres Therapeutics (MCRB) stock options?

The granted stock options have an exercise price of $7.94 per share. This means Rosiello can buy Seres Therapeutics common stock at $7.94 once the options vest, regardless of the market price at that time, subject to the vesting schedule.

How do the newly granted Seres Therapeutics (MCRB) options vest for Robert L. Rosiello?

The options vest in four equal quarterly installments on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027. The final installment may vest earlier if the 2027 annual meeting occurs before July 1, 2027, assuming continued board service.

How many Seres Therapeutics (MCRB) derivative securities does Robert L. Rosiello hold after this transaction?

After the transaction, Rosiello holds 7,508 stock options according to the filing’s post-transaction total. These options give him the right to acquire 7,508 shares of Seres Therapeutics common stock once vested and exercised at the stated exercise price.

Is the Seres Therapeutics (MCRB) Form 4 transaction a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant of stock options, not an open-market stock purchase. The transaction uses code A, indicating a grant or award, and carries a zero-dollar transaction price with a separate $7.94 per share exercise price.